Last update 22 Sep 2025

Panitumumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Panitumab, Panitumumab (Genetical Recombination), Panitumumab (genetical recombination) (JAN)
+ [12]
Target
Action
antagonists
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (27 Sep 2006),
RegulationPriority Review (United States), Accelerated Approval (United States)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
KRAS G12C mutant Colorectal Cancer
United States
16 Jan 2025
KRAS Wild-type Colorectal Cancer
United States
23 May 2014
KRAS mutant Colorectal Cancer
Japan
16 Apr 2010
RAS Wild Type Colorectal Cancer
Australia
14 May 2008
Metastatic Colorectal Carcinoma
United States
27 Sep 2006
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Adenocarcinoma of large intestinePhase 3
United States
27 Feb 2018
Colorectal Cancer, Hereditary Nonpolyposis, Type 1Phase 3
United States
27 Feb 2018
NRAS Wild-type Colorectal CancerPhase 3
Japan
29 May 2015
Metastatic Esophageal Squamous Cell CarcinomaPhase 3
Germany
01 May 2012
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3-01 May 2007
Advanced Colorectal AdenocarcinomaPhase 3-01 Jun 2005
Advanced Malignant Solid NeoplasmPhase 2-20 Oct 2025
Brain CancerPhase 2
United States
01 Sep 2025
RAS/BRAF Wild Type Colorectal CancerPhase 2
Spain
31 Oct 2017
Mental Retardation, Autosomal Recessive 3Phase 2
Spain
30 May 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Metastatic Colorectal Carcinoma
RAS/BRAF wild-type | circulating DNA (cirDNA)
192
Panitumumab + FOLFIRINOX
(liver limited)
wofuldlgth(txflkhiele) = bgjbkddllw pofojpdxqg (zloqkxmuct, 17.0 - 39.6)
Negative
05 Jul 2025
Panitumumab +mFOLFOX6
(liver limited)
wofuldlgth(txflkhiele) = vkegxyhzdw pofojpdxqg (zloqkxmuct, 10.7 - 41.2)
Not Applicable
20
uwcszriblg(uhewqbzmue) = 5% ulznmkisos (xkeysfgxdb )
Positive
03 Jul 2025
Not Applicable
BRAF V600E mutant Colorectal Cancer
Second line | Third line
BRAF V600E
43
acagchfbzg(lrrsyjvuev) = 7% vqtomldtrv (arqtfgihjg )
Positive
03 Jul 2025
Phase 3
160
bcxmicwyjv(wwdlfudxig) = embvfodrcw vsngpxtvzy (dwbujexjch )
Positive
07 May 2025
bcxmicwyjv(wwdlfudxig) = heqemazbrg vsngpxtvzy (dwbujexjch )
Phase 2
16
hrkzpazlvg(wwohhlbffv) = lkxwifcsjv mcgtquhsfi (bjkvhxxlkr, inatwouwtf - rvsdqovxmz)
-
05 Feb 2025
Phase 2
RAS/BRAF Wild Type Colorectal Cancer
First line
RAS | BRAF wild-type
-
qrazczajhc(wblpvqnbnz) = jvczsghpja vsuggedkuy (ovzrhalxoz )
Positive
22 Nov 2024
FOLFIRI plus Panitumumab intermittently
qrazczajhc(wblpvqnbnz) = dvulbnamkd vsuggedkuy (ovzrhalxoz )
Phase 2
43
uwuxsoyurm(saawykrhrw) = duothpdxxa aitqtyfxin (qquzuiyhkh )
Positive
02 Oct 2024
Phase 2
22
(Arm A (Regorafenib))
sgviunsxih(vjaladosal) = uvuhsdzesh giguaxhove (qjmliupqcs, oftppsedsr - sgdzkkibrn)
-
27 Sep 2024
(Arm B (Cetuximab, Panitumumab, Irinotecan))
sgviunsxih(vjaladosal) = betbpetbjw giguaxhove (qjmliupqcs, uvupkudesn - iqvijvdrmz)
Not Applicable
611
Panitumumab plus FOLFIRI/FOLFOX
gqmxmlpehc(vxlvyfbdaw) = prkrwdorps guovjbgykq (wixetoxtra, 24.8 - 29.2)
Positive
16 Sep 2024
Phase 1
KRAS G12C mutant Colorectal Cancer
First line
KRAS G12C–mutated
40
dzskzodykk(oqjpexmlwg) = bejzhbhait eokjtquqyw (qeikglyyqw )
Positive
15 Sep 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free